Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
July 08 2009 - 4:00PM
PR Newswire (US)
MORRISTOWN, N.J., July 8 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE:WPI), a leader in generic and specialty
branded pharmaceuticals, today announced that its subsidiary,
Watson Laboratories, Inc., has received approval from the United
States Food and Drug Administration to market its over-the-counter
Nicotine Polacrilex Gum USP, 2 mg and 4 mg strengths in the coated
fruit and cinnamon flavors. Nicotine Polacrilex Gum coated fruit
and cinnamon flavors are the generic equivalent of GlaxoSmithKline
Consumer Healthcare's Nicorette Fruit Chill(R) and Cinnamon
Surge(TM) Coated gums, which are used as an aid to smoking
cessation. The market for over-the-counter nicotine gum had annual
sales of over $305 million for the twelve months ending March 2009,
according to IRI sales data. Watson will make the products
available to customers immediately. About Watson Pharmaceuticals,
Inc. Watson Pharmaceuticals, Inc. is a global leader in the
development and distribution of pharmaceuticals with a broad
portfolio of generic products and a specialized portfolio of brand
pharmaceuticals focused on Urology, Women's Health and
Nephrology/Medical. For press release and other company
information, visit Watson Pharmaceuticals' Web site at
http://www.watson.com/. Forward-Looking Statement Any statements
contained in this press release that refer to future events or
other non-historical facts are forward-looking statements that
reflect Watson's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Watson disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Watson's current expectations depending upon a
number of factors affecting Watson's business. These factors
include, among others, the impact of competitive products and
pricing; market acceptance of and continued demand for Watson's
products; difficulties or delays in manufacturing; the difficulty
of predicting the timing or outcome of FDA or other regulatory
agency approvals or actions, if any; patents and other intellectual
property rights held by third parties; and other risks and
uncertainties detailed in Watson's periodic public filings with the
Securities and Exchange Commission, including but not limited to
Watson's Annual Report on Form 10-K for the year ended December 31,
2008. Nicorette Fruit Chill(R) is a registered trademark of
GlaxoSmithKline Consumer Healthcare, L.P. Nicorette Cinnamon
Surge(TM) is a trademark of GlaxoSmithKline Consumer Healthcare,
L.P. (Logo:
http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)
http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO
http://photoarchive.ap.org/ DATASOURCE: Watson Pharmaceuticals,
Inc. CONTACT: Patty Eisenhaur of Watson Pharmaceuticals, Inc.,
+1-951-493-5611 Web Site: http://www.watson.com/
Copyright